{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12","value":"38.5"},{"groupId":"OG001","spread":"21","value":"154"},{"groupId":"OG002","spread":"14","value":"139"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"N of 1, Individual data presented, no CV value.","groupId":"OG000","spread":"NA","value":"70.5"},{"comment":"N of 1, Individual data presented, no CV value.","groupId":"OG001","spread":"NA","value":"179"},{"groupId":"OG002","spread":"25","value":"220"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 7 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m\\^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.","id":"OG000","title":"100 mg Tabalumab+BTZ IV+Dex"},{"description":"Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle. BTZ, 1.3 mg/m\\^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ IV.","id":"OG001","title":"300 mg Tabalumab+ IV BTZ +Dex"},{"description":"Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle. BTZ, 1.3 mg/m\\^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ SC.","id":"OG002","title":"300 mg Tabalumab+ SC BTZ +Dex"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received at least 1 dose of any study drug and had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1: 6 + or - hours after bortezomib (BTZ); Cycle 7, Day 1: immediately post BTZ dose and 2 hours after tabalumab","title":"Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Tabalumab (LY2127399)","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (μg/mL)"}